Skip to main content
DEXCOM INC logo

DEXCOM INC - Investor Relations & Filings

Listed IPO Jun 2005
Ticker · DXCM ISIN · US2521311074 LEI · 549300YSK3QDSFR5EU59 US Manufacturing
Filings indexed 2,053 across all filing types
Latest filing 2024-02-15 Capital/Financing Update
Country US United States of America
Listing US DXCM · 16 venues

Key figures FY2025

Period ended 2025-12-31 · USD
Headline annual figures for DEXCOM INC, fiscal year 2025, reported in USD, with the source filing for each figure.
Total Revenues USD 4.66B per the Annual Report filed 2026-02-12
Net Income USD 836.30M per the Annual Report filed 2026-02-12
Total Assets USD 6.34B per the Annual Report filed 2026-02-12
Total Equity USD 2.75B per the Annual Report filed 2026-02-12
Cash from Ops USD 1.44B per the Annual Report filed 2026-02-12

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About DEXCOM INC

https://www.dexcom.com/

Dexcom Inc. is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes management. The company's core technology consists of wearable sensors that continuously measure and transmit glucose levels to a compatible smart device or receiver, providing real-time data, alerts, and trend information. Its product portfolio, which includes the Dexcom G6, G7, and the over-the-counter Stelo Glucose Biosensor System, is designed to help people with diabetes make treatment decisions without traditional fingersticks. The systems also assist users in understanding how lifestyle factors like diet and exercise impact their glucose levels, empowering them to take greater control of their health.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement regarding the termination of warrants with Bank of America, including details about the agreement and its financial implications. There are no comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a transcript, proxy, or earnings release. It is a regulatory filing announcing a significant corporate event related to capital structure (warrant termination and share issuance). Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (6006 characters) and detailed description support this classification with high confidence.
2024-02-15 English
SCHEDULE 13G/A
Major Shareholding Notification
2024-02-13 English
10-K
Annual Report FY 2023
2024-02-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 8, 2024, by DexCom, Inc. It announces the issuance of a press release with financial results for the quarter and year ended December 31, 2023. The text explicitly states that the press release is furnished as an exhibit and that the information is not "filed" for purposes of Section 18 of the Exchange Act, indicating this is an announcement rather than the full earnings report itself. The document length is 3772 characters, which is relatively short and consistent with an announcement rather than a full report. The content corresponds to an initial announcement of quarterly and annual financial results, which fits the definition of an Earnings Release (ER). FY 2023
2024-02-08 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-01-25 English
PRIMARY DOCUMENT
Director's Dealing
2024-01-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.